Literature DB >> 8989236

Methylprednisolone exposure, rather than dose, predicts adrenal suppression and growth inhibition in children with liver and renal transplants.

S Sarna1, K Hoppu, P J Neuvonen, J Laine, C Holmberg.   

Abstract

Some patients receiving glucocorticoids develop adverse effects even with very low doses, whereas others fail to achieve the desired effects with the usual therapeutic doses. We hypothesized that glucocorticoid exposure, rather than the dose, would predict the development of adverse effects in children receiving long-term glucocorticoid treatment. Sixteen liver and 10 renal transplant recipients on triple immunosuppression were studied. Serum total methylprednisolone (MP) and cortisol were determined before and up to 10 h after peroral MP administration. Heights were recorded 6 months before and after the study day. The MP dose (in milligrams per kilogram) was not correlated with the serum cortisol concentration or with the change in height SD score. The area under the serum MP time vs. concentration curve was inversely related to the serum cortisol concentration and to the height SD score, and was the best predictor of both adrenal function and growth. Dosing according to area under the serum MP time vs. concentration curve in children receiving long-term glucocorticoid treatment may substantially reduce the incidence of adverse effects without affecting therapeutic efficacy.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 8989236     DOI: 10.1210/jcem.82.1.3639

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  8 in total

1.  Dosing of glucocorticosteroids in nephrotic syndrome.

Authors:  Otto Mehls; Peter F Hoyer
Journal:  Pediatr Nephrol       Date:  2011-09-09       Impact factor: 3.714

Review 2.  Steroid withdrawal in pediatric and adult renal transplant recipients.

Authors:  Burkhard Tönshoff; Britta Höcker; Lutz T Weber
Journal:  Pediatr Nephrol       Date:  2005-01-14       Impact factor: 3.714

3.  Pharmacokinetic, pharmacodynamic, and pharmacogenetic determinants of osteonecrosis in children with acute lymphoblastic leukemia.

Authors:  Jitesh D Kawedia; Sue C Kaste; Deqing Pei; John C Panetta; Xiangjun Cai; Cheng Cheng; Geoffrey Neale; Scott C Howard; William E Evans; Ching-Hon Pui; Mary V Relling
Journal:  Blood       Date:  2010-12-10       Impact factor: 22.113

4.  Glucocorticoid pharmacokinetics and growth retardation in children with renal transplants.

Authors:  Claire Chavatte; Geneviève Guest; Virginie Proust; Christine Le Bihan; François Gimenez; Anne Maisin; Chantal Loirat; Agnès Mogenet; Jean-Louis Bresson; Régis Hankard; Michel Broyer; Patrick Niaudet; Eric Singlas
Journal:  Pediatr Nephrol       Date:  2004-06-03       Impact factor: 3.714

Review 5.  Adverse effects of immunosuppression in pediatric solid organ transplantation.

Authors:  Kristine S Schonder; George V Mazariegos; Robert J Weber
Journal:  Paediatr Drugs       Date:  2010       Impact factor: 3.022

Review 6.  Growth after renal transplantation.

Authors:  Jérôme Harambat; Pierre Cochat
Journal:  Pediatr Nephrol       Date:  2008-03-26       Impact factor: 3.714

7.  Antileukemic Efficacy of Continuous vs Discontinuous Dexamethasone in Murine Models of Acute Lymphoblastic Leukemia.

Authors:  Laura B Ramsey; Laura J Janke; Monique A Payton; Xiangjun Cai; Steven W Paugh; Seth E Karol; Landry Kamdem Kamdem; Cheng Cheng; Richard T Williams; Sima Jeha; Ching-Hon Pui; William E Evans; Mary V Relling
Journal:  PLoS One       Date:  2015-08-07       Impact factor: 3.240

Review 8.  Growth in children on kidney replacement therapy: a review of data from patient registries.

Authors:  Marjolein Bonthuis; Jérôme Harambat; Kitty J Jager; Enrico Vidal
Journal:  Pediatr Nephrol       Date:  2021-06-18       Impact factor: 3.714

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.